Physician profile
Diane Bolduc
NPI 1174537047
$1,717.59
in general payments reported to CMS, 2019-2025
18 companies · $922 in 2025
The $922 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $3.82 · 2022: $36.56 · 2023: $180 · 2024: $575 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.22 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $477.77 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $207.72 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $202.41 | 2024-2025 | |
| Pfizer INC. | $117.29 | 2023-2025 | |
| Glaxosmithkline, LLC. | $110.65 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $98.11 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $78.78 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $71.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $67.68 | 2023-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Phathom Pharmaceuticals, INC. | $55.86 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $54.99 | 2025 | Auvelity |
| Revance Therapeutics, INC. | $50.10 | 2025 | Daxxify |
| Edwards Lifesciences Corporation | $35.14 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lilly USA, LLC | $28.69 | 2023-2024 | Mounjaro |
| Vertex Pharmaceuticals Incorporated | $20.96 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.17 | 2025 | Veozah |
| Ultragenyx Pharmaceutical INC. | $17.15 | 2022 | |
| Travere Therapeutics, INC. | $3.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Bolduc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.